A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Active:	No
Cancer Type:	Lung Cancer	NCT ID:	NCT05060016
Trial Phases:	Phase II	Protocol IDs:	20200491 (primary) NCI-2022-01702 2021-002566-40
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Amgen, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05060016

Summary

The main aim of this study is to:

- evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors
version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1
only

- evaluate anti-tumor activity of tarlatamab as determined by objective response rate
(ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2

- evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose
of tarlatamab for Part 3

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.